These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 14574916)

  • 21. Alternative schedules with irinotecan.
    Diasio R
    Semin Oncol; 2003 Aug; 30(4 Suppl 12):18-24. PubMed ID: 14508723
    [No Abstract]   [Full Text] [Related]  

  • 22. Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancer.
    Teufel A; Steinmann S; Siebler J; Zanke C; Hohl H; Adami B; Schroeder M; Klein O; Höhler T; Galle PR; Heike M; Moehler M
    BMC Cancer; 2004 Jul; 4():38. PubMed ID: 15265233
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Irinotecan/5-FU/leucovorin, oxaliplatin/5-FU/leucovorin, and oxaliplatin/irinotecan are each effective in the treatment of 5-FU-resistant advanced colorectal cancer.
    Fisher MD
    Clin Colorectal Cancer; 2001 Aug; 1(2):85-6. PubMed ID: 12445365
    [No Abstract]   [Full Text] [Related]  

  • 24. [Capecitabine and irinotecan].
    Gasperoni S
    Suppl Tumori; 2004; 3(4):S107-8. PubMed ID: 15206231
    [No Abstract]   [Full Text] [Related]  

  • 25. Biweekly oxaliplatin plus irinotecan and folinic acid-modulated 5-fluorouracil: a phase II study in pretreated patients with metastatic colorectal cancer.
    Comella P; Massidda B; Palmeri S; Putzu C; De Rosa V; Izzo F; Fiore F; Casaretti R; Sandomenico C
    Anticancer Drugs; 2006 Sep; 17(8):985-92. PubMed ID: 16940809
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An alternating regimen of irinotecan/ 5-fluorouracil/folinic acid and oxaliplatin/ 5-fluorouracil/folinic acid in metastatic colorectal cancer: a Phase II trial.
    Ferrari V; Valcamonico F; Amoroso V; Simoncini E; Vassalli L; Marpicati P; Rangoni G; Grisanti S; Pasinetti N; Marini G
    Oncology; 2005; 69(4):283-9. PubMed ID: 16282707
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Systemic chemotherapy for metastatic colorectal cancer: reasons to combine.
    Calvo E
    Clin Colorectal Cancer; 2002 Nov; 2(3):170-2. PubMed ID: 12482333
    [No Abstract]   [Full Text] [Related]  

  • 28. Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer.
    Chau I; Webb A; Cunningham D; Hill M; Waters JS; Norman A; Massey A
    Br J Cancer; 2001 Nov; 85(9):1258-64. PubMed ID: 11720458
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer.
    Pignon JP; Ducreux M
    N Engl J Med; 2001 Jan; 344(4):306; author reply 306-7. PubMed ID: 11191663
    [No Abstract]   [Full Text] [Related]  

  • 30. Toxicity analysis of the 5-day bolus 5-fluorouracil/folinic acid regimen for the treatment of colorectal carcinoma from 2 randomized controlled trials: a concern about dose.
    Vincent M; Ho C; Tomiak A; Winquist E; Whiston F; Stitt L
    Clin Colorectal Cancer; 2002 Aug; 2(2):111-8. PubMed ID: 12453326
    [TBL] [Abstract][Full Text] [Related]  

  • 31. FOLFIRI plus bevacizumab as a first-line treatment for Japanese patients with metastatic colorectal cancer: a JACCRO CC-03 multicenter phase II study.
    Kochi M; Akiyama Y; Aoki T; Hagiwara K; Takahashi T; Hironaka K; Teranishi F; Osuka F; Takeuchi M; Fujii M; Nakajima T
    Cancer Chemother Pharmacol; 2013 Nov; 72(5):1097-102. PubMed ID: 24057041
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Management and types of side effects in chemotherapy for lung cancer].
    Yoshida K
    Nihon Rinsho; 2002 May; 60 Suppl 5():384-7. PubMed ID: 12101694
    [No Abstract]   [Full Text] [Related]  

  • 33. ERBITUX as a single agent and in combination in colorectal carcinoma.
    Expert Rev Anticancer Ther; 2002 Jun; 2(3):242. PubMed ID: 12113039
    [No Abstract]   [Full Text] [Related]  

  • 34. 5-fluorouracil modulated by leucovorin, methotrexate and mitomycin: highly effective, low-cost chemotherapy for advanced colorectal cancer.
    Sobrero A; Guglielmi A; Cirillo M; Recaldin E; Frassineti GL; Aschele C; Ravaioli A; Testore P; Caroti C; Gallo L; Pessi MA; Cortesi E; Turci D; Grossi F; Labianca R
    Br J Cancer; 2001 Apr; 84(8):1023-8. PubMed ID: 11308248
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Turning point for colorectal cancer clinical trials.
    Meropol NJ
    J Clin Oncol; 2006 Jul; 24(21):3322-4. PubMed ID: 16849744
    [No Abstract]   [Full Text] [Related]  

  • 36. A clinical study of fluorouracil.
    Nadler SH; Moore GE
    Surg Gynecol Obstet; 1968 Dec; 127(6):1210-4. PubMed ID: 4882472
    [No Abstract]   [Full Text] [Related]  

  • 37. Evolution of systemic therapy for metastatic colorectal cancer.
    Geh JI; Ma YT
    Colorectal Dis; 2011 Aug; 13(8):852-4. PubMed ID: 21762349
    [No Abstract]   [Full Text] [Related]  

  • 38. [Retrospective study of irinotecan plus fluorouracil and l-leucovorin chemotherapy for advanced and metastatic colorectal cancer].
    Matsukura S; Samejima R; Tanaka M; Hidaka K
    Gan To Kagaku Ryoho; 2004 Jun; 31(6):893-6. PubMed ID: 15222107
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Standard therapy of CPT-11 for colorectal cancer].
    Saitoh S; Sakata Y
    Gan To Kagaku Ryoho; 2001 Oct; 28(10):1345-51. PubMed ID: 11681240
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New treatments for colorectal cancer.
    FDA Consum; 2004; 38(3):17. PubMed ID: 15218840
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.